India's Dependence on Chinese Drug Ingredients

Why India's large generic industry relies on China for active pharmaceutical ingredients, the risks this creates, and the push to make them at home.

Every medicine contains an active pharmaceutical ingredient, or API, the chemical that does the work. India is a giant in making finished generic medicines, but it imports a large share of its APIs and their chemical building blocks from China.

How this happened

In the 1980s and 1990s, India made many of its own APIs. But Chinese producers grew rapidly with huge scale, cheap power and government support, offering lower prices. Many Indian firms found it cheaper to import than to make.

The risk

In early 2020, as COVID-19 shut Chinese factories, prices of some APIs jumped and supplies were disrupted. India briefly restricted exports of some medicines like paracetamol.
Political tensions after 2020 added to concerns.

The policy response

Production Linked Incentive schemes for critical APIs and key starting materials, launched in 2020.
Bulk drug parks with shared infrastructure in several states.
Support for fermentation-based APIs, where China is especially dominant.

Challenges

Chinese firms still have large cost advantages.
Building chemical plants takes years and faces environmental clearances.
Success depends on scale and efficiency, not just subsidies.

Why it matters

Medicine security affects public health. Diversifying supply reduces the risk that a single shock cuts off essential drugs.

The paracetamol scare

In early 2020, API prices for paracetamol spiked as Chinese supply faltered. Indian manufacturers scrambled for stock, and the government restricted some exports to protect domestic supply.

Thinking India makes all its drugs from scratch

India is strong in finished medicines but relies heavily on imported ingredients.

Key takeaways

India imports many APIs and starting materials from China.
The 2020 disruption exposed supply risks.
PLI schemes and bulk drug parks aim to build domestic production.
Cost gaps and slow plant building remain challenges.